Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RVMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -387.32M
March 31, 2026 -354.16M
December 31, 2025 -274.24M
September 30, 2025 -207.31M
June 30, 2025 -221.76M
March 31, 2025 -194.44M
December 31, 2024 -138.29M
September 30, 2024 -130.42M
June 30, 2024 -128.17M
March 31, 2024 -160.56M
December 31, 2023 -120.56M
September 30, 2023 -100.50M
June 30, 2023 -67.12M
March 31, 2023 -62.39M
December 31, 2022 -61.79M
Date Value
September 30, 2022 -51.74M
June 30, 2022 -55.72M
March 31, 2022 -55.16M
December 31, 2021 -39.26M
September 30, 2021 -36.59M
June 30, 2021 -34.08M
March 31, 2021 -37.25M
December 31, 2020 -25.03M
September 30, 2020 -27.02M
June 30, 2020 -19.99M
March 31, 2020 -28.02M
December 31, 2019
September 30, 2019
June 30, 2019 -11.50M
March 31, 2019 -12.60M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Tango Therapeutics, Inc. -38.87M
Erasca, Inc. -27.27M
Moderna, Inc. -526.00M
Arrowhead Pharmaceuticals, Inc. -177.47M
Intellia Therapeutics, Inc. -83.11M